Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model

Almalki ZS, Alshammari MM, Almazrou SH, Alqahtani OAA, Alkhayat MR, Alnemari SF, Mukhemair HS, Alkredeas SM, Alsuhibani AA, Asiri BY, Alalawi TN, Alahmari AK, Alotaibi FO

ClinicoEconomics and Outcomes Research 2025, 17:217-232

Published Date: 20 March 2025